



Udlercollage © Gorodenkoff/shutterstock.com, U.PSD/shutterstock.com, PublicDomainPictures/es/istockphoto.com

***The use of EV data and  
common inspection findings***

***EMA Stakeholder Forum on EV and Signal/Data Management***

**Dr. Eva-Maria Jahn**  
PV inspector

Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel  
Federal Institute for Vaccines and Biomedicines



Das Paul-Ehrlich-Institut ist ein Bundesinstitut im Geschäftsbereich des Bundesministeriums für Gesundheit.

*The Paul-Ehrlich-Institut is an Agency of the German Federal Ministry of Health.*

**Paul-Ehrlich-Institut**



# Disclaimer

The views expressed in this presentation are the personal views of the presenter(s). They shall not be understood or cited as opinions of the Paul-Ehrlich-Institut. The presenter has not received any funding or grants from companies or from associations representing companies.

The reproduction and distribution of information and data from this presentation (text, image, graphics) is prohibited without the prior written consent of the presenter and the Media and Public Relations Unit at the Paul-Ehrlich-Institut ([presse@pei.de](mailto:presse@pei.de)). This also applies to the reproduction and distribution of excerpts from the presentation. No liability for the topicality and completeness of the information provided will be assumed.

# COMPLIANCE DATA IN EUDRAVIGILANCE

- Performance indicator dashboard
- Cases reported late 15/90 days reporting period
- Cases transmitted with errors without correct follow up
- Master cases and duplicate reports
- Common inspection findings

# Performance indicator dashboard


- ✓ PM and CT data
- ✓ 7/15/90 days reporting period
- ✓ Initial and follow-up cases
- ✓ Case amendments
- ✓ Nullifications

# MAH performance indicator dashboard


MAH/NCA	Serious ICSRs-EVPM-Initial(15 days)		Serious ICSRs-EVPM-Follow-up(15 days)		Serious ICSRs-EVCTM-Initial(7 days)-Fatal / Life threatening		Serious ICSRs-EVCTM-Follow-up(15 days)-Fatal / Life threatening		Serious ICSRs-EVCTM-Initial(15 days)-Not Fatal / Life threatening		Serious ICSRs-EVCTM-Follow-up(15 days)-Not Fatal / Life threatening	
	% compliance	Total ICSR	% compliance	Total ICSR	% compliance	Total ICSR	% compliance	Total ICSR	% compliance	Total ICSR	% compliance	Total ICSR
	97,73%	4.183	92,24%	3.275	90,91%	55	96,27%	322,00	100,00%	281,00	96,82%	1.005

Non Serious ICSRs-EVPM-Initial(90 days)		Non Serious ICSRs-EVPM-Follow-up(90 days)		EVPM	EVCTM	EVPM	EVCTM	EVPM	EVCTM
% compliance	Total ICSR	% compliance	Total ICSR	Number of initial ICSR with follow-up	Number of initial ICSR with follow-up	Number of amendment ICSR	Number of amendment ICSR	Number of nullification ICSR	Number of nullification ICSR
99,83%	596	96,53%	259	1068	251	357	31	110	7

# ICSRs reported within/outside 7/15 days



# ICSRs reported within/outside 7/15 days



# Non compliance line listing

## Request information regarding the late cases

Organisation Type		MAH/Sponsor		Organisation	EV Document Type
Type of Transmission				EVPM Number of ICSRs - Initial	EVPM Number of ICSRs - Follow-up
Expedited Reporting Time (in Days)	EV Local Report Number	EV World Wide Unique Case Identifier			
21				1	
23					1
24				1	
29				1	
48					1


## Non-serious cases

Organisation Type		MAH/Sponsor		Organisation	EVPM Number of ICSRs - Initial	EVPM Number of ICSRs - Follow-up
Transmission Type				EVPM Number of ICSRs - Initial	EVPM Number of ICSRs - Follow-up	
Expedited Reporting Time (Days)	EV Local Report Number	EV World Wide Unique Case Identifier				
115					1	
217				1		
239				1		
242				1		

# ICSRs reported for a selected drug substance

Organisation Type **MAH/Sponsor** ▼

Organisation



# Non compliance data

- ✓ Check compliance rate and the number of cases affected
- ✓ Break down to smaller periods, e.g. monthly or quarterly
- ✓ Compare with PSMF Annex F data
- ✓ Document request: assessment and action taken for late cases, deviations/CAPAs raised?
- ✓ Summary slides for the inspection

# Case transmissions with errors without correct follow up

- ✓ Get line listing of cases for the selected MAH and period
- ✓ Request documented evidence of corrections for the respective case and ACKs/xml files

# Acknowledgement codes

- ✓ ACK.A.4 Transmission acknowledgement code
- ✓ Information on the submitted batch
  - AA – *Application Acknowledgement Accept* (message successfully processed, no further action)
  - AE – *Application Acknowledgment Error* (error detected, error response has additional detail, some ICSR message(s) need further action)
  - AR – *Application Acknowledgment Reject* (parsing error, no data extracted, **re-send the entire transaction**)

# Acknowledgement codes

- ✓ ACK.B.r.6 Acknowledgement code for the ICSR message
- ✓ Information on the loading of the ICSR message
  - CA – Commit Accept (the ICSR message successfully loaded)
  - CR – Commit Reject (the ICSR message contains fatal error that prevents the ICSR from being loaded)
    - ➔ re-submission required

# Acknowledgement codes

- ✓ ACK.B.r.7 Error / Warning message or comment
- ✓ Description of the error(s) detected in the ICH ICSR message
- ✓ Non fatal warning message when ACK.B.r.6 is “CA”



Recommendation for the MAH to review warning ACKs  
with focus on relevant warnings to enhance ICSR quality

# Master cases and duplicate reports

Cluster ID	EV World Wide Unique Case Identifier	Cluster Role	Local Report Number	Sender
		Master		EUDRAVIGILANCE WEB TRADER
		Duplicate		MAH A
		Duplicate		MAH A
		Duplicate		MAH A
		Duplicate		MAH A
		Duplicate		MAH A
		Duplicate		MAH B
		Duplicate		MAH D
		Duplicate		MAH E
		Duplicate		MAH F
		Duplicate		MAH G

Each colour represents a separate MAH

# Master cases and duplicate reports

- ✓ Select cases from the MAH to be inspected
- ✓ Ask for the duplicate check procedure and documentation
- ✓ Check selected cases in the safety data base of the MAH
- ✓ Date case received, duplicate check, reported to EV?
- ✓ Which elements are looked at for duplicate check?
- ✓ How can several duplicates from the same MAH be found in EV?




# Common findings related to ICSR quality

- ✓ Inconsistencies between narrative and structured fields
- ✓ Not all information in narrative entered into structured fields, e.g. tests, patient's medical history etc.
- ✓ Incorrect coding of reported events, e.g. associated symptoms of a diagnose were entered as reaction
- ✓ Maternal exposure, missed dose, product issue, therapy cessation without associated event entered as reaction
- ✓ Events occurring at different time points were captured in one case
- ✓ Appropriate nullflavor not used for patient initials, batch number etc.

# Common findings related to ICSR reporting

- ✓ Overreporting of invalid reports without an identifiable patient, no reported event, or suspected drug as placebo
- ✓ Overreporting of cases with outcome death, insufficient follow-up, no medical assessment and coding to a fitting LLT
- ✓ Overreporting of special situation cases
- ✓ Incorrect seriousness assessment
- ✓ Incorrect/missing causality assessment
- ✓ Incorrect handling of follow-up information, new case versus case amendment



THANK YOU VERY MUCH  
FOR YOUR ATTENTION  
ANY QUESTIONS ?

[PhV-Inspektionen@pei.de](mailto:PhV-Inspektionen@pei.de)